DNA as a prognostic marker in advanced high-grade prostatic cancer. A preliminary report. SPCG-I study.
This is a presentation of some preliminary data from SPCG-I, a multicenter study started in 1984 by the Scandinavian Prostatic Cancer Group. It is a randomized double-blind study comparing estramustine phosphate and diethylstilbestrol in the primary treatment of 195 patients with T1-4, NX, M1, G2-3 prostatic cancer. The code is not yet broken. This presentation describes the impact of the pretreatment parameters performance status, pain, tumor burden, grade and DNA-ploidy of the prostate tumor, on time to progression and overall survival. DNA studies have so far only been completed in 66 of the 195 patients. For the whole group of 195 patients, pain (p less than 0.004) and tumor grade (p less than 0.02) had the most significant impact on time to progression, and performance status (p less than 0.01) and grade (p less than 0.03) on overall survival. In the small group of 66 patients where the DNA pattern of the primary tumor was evaluated, no parameter had any significant correlation to time to progression and overall survival. This study is still continuing.
Hedlund
P O
PO
Department of Urology, Karolinska Hospital, Stockholm, Sweden.
Esposti
P
P
Falkmer
U
U
Jacobsson
H
H
D004273:DNA, Neoplasm / Q000235:genetics*; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011003:Ploidies; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016019:Survival Analysis
D004273:DNA, Neoplasm; D004961:Estramustine; D004054:Diethylstilbestrol